WAIKOLOA, Hawaii — The recent progress and future development of gene therapy could help patients with wet age-related macular degeneration maintain vision, according to a speaker at Retina 2026.
Allen C. Ho, MD, of Wills Eye Hospital, said gene therapy started in the subretinal space with gene replacement therapy for Leber congenital amaurosis, and since that first FDA approval in 2017, there have been 30 gene therapies approved across all of medicine.
{{VIDEO}}
“We’re bringing it back to the retina,” he said.
In 2025, the FDA approved Encelto (revakinagene taroretcel-lwey, Neurotech